# Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Study · id `cardio:ct-nct07582835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07582835](<https://clinicaltrials.gov/study/NCT07582835>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07582835

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 355 participants.

## Technical summary

Registry record NCT07582835. Randomized; no masking; primary purpose treatment. Start 2026-04-20 (anticipated); primary completion 2028-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 355 participants (planned count; ClinicalTrials.gov record NCT07582835, source copy `cardio:ctgov-nct07582835-2026-05-13`, retrieved 2026-10-26)
- Planned start: 2026-04-20 (anticipated) (ClinicalTrials.gov record NCT07582835, source copy `cardio:ctgov-nct07582835-2026-05-13`, retrieved 2026-10-26)
- Primary completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07582835, source copy `cardio:ctgov-nct07582835-2026-05-13`, retrieved 2026-10-26)
- Completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07582835, source copy `cardio:ctgov-nct07582835-2026-05-13`, retrieved 2026-10-26)
- Countries: Switzerland (ClinicalTrials.gov record NCT07582835, source copy `cardio:ctgov-nct07582835-2026-05-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07582835-2026-05-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
- Acronym: HI-TECH 2
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Condition: Acute Coronary Syndromes
- Condition: Antiplatelet Therapy
- Condition: Single Antiplatelet Therapy
- Condition: Coagulation Factors
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Prasugrel
- Lead sponsor: Cardiocentro Ticino
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)

## Provenance

Content hash: 854df28a804cde19f9cb96d6fcfcc60bdd32f054f73bc048503e4f672c9a9132
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
